top of page

Project Panacea: Where Synthetic Bio Meets Real-World Impact

  • maninon0
  • Aug 4
  • 1 min read

A non-invasive breast cancer therapy?

 

Yes, and it’s closer than you think.

 

Project Panacea is the bold new collaboration between TheraSyn Bio and Rubix LS, combining synthetic biology + real-world data to take on one of oncology’s biggest challenges and actually make it equitable.

 

What’s inside the case study:

  •  A topical therapy rooted in synthetic bio

  •  Real-time simulation using digital twins

  •  18M+ diverse patient datasets driving precision

  •  Designed for historically excluded patients

  •  What's next as clinical trials prepare to launch in 2026

 

Hear from Daisy Gallagher and Reginald Swift on how this collaboration is setting a new standard for oncology clinical trials.

 

Read the full case study here.

 

image.png
  • LinkedIn
  • Facebook
  • Twitter
  • Instagram
  • Whatsapp

Rubix LS: We’re the Health Outcomes Architect Company, designing a healthier future for every community.

image.png

Join our mailing list

image.png
image.png

Designing health outcomes for the end in mind
is best for patients & the industries that serve them.

Our mission is to design health outcomes that serve every community by addressing the full range of factors that drive health from biological to environmental to socioeconomic. We are pioneers of holistic, precision-focused approaches that go beyond traditional medicine and looks at deeper systemic factors affecting health and design for that that benefits both patients, the healthcare system, and the industries that support all of it.

Copyright © 2025 Rubix Life Sciences | Privacy Policy

bottom of page